Portal de investigación
Neuroprotective Effect of IND1316, an Indole-Based AMPK Activator, in Animal Models of Huntington Disease.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Vela, Marta
- Garcia-Gimeno, Maria Adelaida
- Cumella, Jose
- Lagartera, Laura
- Perez, Concepcion
- Priego, Eva-Maria
- Campos, Angela
- Sanz, Pascual
- Castro, Ana
Grupos
Abstract
Aggregation of mutant huntingtin, because of an expanded polyglutamine track, underlies the cause of neurodegeneration in Huntington disease (HD). However, it remains unclear how some alterations at the cellular level lead to specific structural changes in HD brains. In this context, the neuroprotective effect of the activation of AMP-activated protein kinase (AMPK) appears to be a determinant factor in several neurodegenerative diseases, including HD. In the present work, we describe a series of indole-derived compounds able to activate AMPK at the cellular level. By using animal models of HD (both worms and mice), we demonstrate the in vivo efficacy of one of these compounds (IND1316), confirming that it can reduce the neuropathological symptoms of this disease. Taken together, in vivo results and in silico studies of druggability, allow us to suggest that IND1316 could be considered as a promising new lead compound for the treatment of HD and other central nervous system diseases in which the activation of AMPK results in neuroprotection.
Datos de la publicación
- ISSN/ISSNe:
- 1948-7193, 1948-7193
- Tipo:
- Article
- Páginas:
- 275-287
- Factor de Impacto:
- 1,140 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
ACS CHEMICAL NEUROSCIENCE American Chemical Society
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- *ADME in silico; *AMPK; *C. elegans models; *Huntington disease mouse models; *indole derivatives; *neuroprotection; *polyQ toxicity
Proyectos asociados
MOLECULAR MECHANISMS OF PROTEIN AGGREGATION IN VITRO AND IN VIVO MODELS OF HUNTINGTON DISEASE
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
CP11/00090 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012
MECHAGGRENAMICS. MECHANISMS OF CELL DYSFUNCTION BY AGGREGATION DYNAMICS OF POLYQ-CONTAINING PROTEINS
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
322034_MARIE_CURIE_VAZQUEZ_FP7-PEOPLE-2012-CIG . COMISION EUROPEA; ASOCIACION VALENCIANA DE ENFERMEDAD HUNTINGTON . 2012
COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
ESTRATEGIAS TERAPÉUTICAS CONTRA LA TOXICIDAD PRODUCIDA POR PÉPTIDOS Y RNA CODIFICADOS POR EL ALELO MUTANTE DE HTT EN LA ENFERMEDAD DE HUNTINGTON.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
PI14/00949 . INSTITUTO DE SALUD CARLOS III . 2015
MODELOS DE HÍGADO AISLADO PERFUNDIDO PARA EL RESCATE DE ÓRGANOS Y TRASLACIÓN DE LA TERAPIA GÉNICA EN EL TRASPLANTE: ESCENARIOS HUMANO "EX VIVO" Y PORCINO "IN VIVO"
Investigador Principal: RAFAEL LÓPEZ ANDÚJAR
2017_0270_CRC_LOPEZ . FUNDACION MUTUA MADRILEÑA . 2017
Mecanismos y estrategias terapéuticas en la Enfermedad de Huntington mediante metformina y salicilato.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
PI17/00011 . INSTITUTO DE SALUD CARLOS III . 2018
Estrategia terapéutica contra la enfermedad de Huntington mediante la activación sinergística de AMPK.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
2018_0381_CRC_RAMON ARECES_VAZQUEZ . FUNDACIÓN RAMÓN ARECES . 2019
Tu hospital investiga RRI.
Investigador Principal: ANA ISABEL JUAN ROCH
FCT-18-14018 . FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA . 2019
Randomized, double-blind, placebo-controlled study to evaluate the effect of metformin, an activator of AMPK, on cognitive decline in patients with Huntington's disease. TEMET-HD
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
ICI19/00014 . INSTITUTO DE SALUD CARLOS III . 2020
Activación sinérgica de AMPK para detener el progreso de la enfermedad de Huntington
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
ACIF/2020/366 . CONSELLERIA DE EDUCACION . 2020
Modulating the activity of genes controlling fat metabolism as a therapeutic strategy in Huntington disease.
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
PI20/00114 . INSTITUTO DE SALUD CARLOS III . 2021
Plataforma ISCIII de Biobancos y Biomodelos
Investigador Principal: JOSÉ VICENTE CERVERA ZAMORA
PT20/00179 . INSTITUTO DE SALUD CARLOS III . 2021
Cita
Vela M,Garcia MA,Sanchis A,Bono J,Cumella J,Lagartera L,Perez C,Priego E,Campos A,Sanz P,Vazquez RP,Castro A. Neuroprotective Effect of IND1316, an Indole-Based AMPK Activator, in Animal Models of Huntington Disease. ACS CHEM NEUROSCI. 2022. 13. (2):p. 275-287. IF:5,000. (2).